Medicamen Biotech Ltd

Medicamen Biotec Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Medicamen Biotech Ltd

₹ 450 -0.64%
26 Jul - close price
medicamen.com BSE: 531146 NSE: MEDICAMEQ
About

Incorporated in 1993, Medicamen Biotech Ltd is a research-led pharmaceutical company involved in developing, manufacturing, and marketing generic finished dosage formulations, and Oncology Formulations[1]

Key Points

Business Overview:[1][2][3]
MBL, a subsidiary of Shivalik Rasayan Ltd with 41.6% ownership, is an integrated Pharmaceutical and Life Sciences Solution Provider. They manufacture pharmaceutical formulations, primarily focusing on oncology therapeutics and generics, distributed through wholesale drug distributors and sold to institutional segments such as government and semi-government institutions, and hospitals. Their formulations cover beta-lactam, non-beta-lactam, and cephalosporin drugs for overseas and domestic markets.

Website BSE NSE
  • Market Cap ₹ 572 Cr.
  • Current Price ₹ 450
  • High / Low ₹ 904 / 355
  • Stock P/E 43.0
  • Book Value ₹ 165
  • Dividend Yield 0.22 %
  • ROCE 9.28 %
  • ROE 6.60 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Debtor days have improved from 152 to 102 days.

Cons

  • Stock is trading at 2.73 times its book value
  • Company has a low return on equity of 8.41% over last 3 years.
  • Dividend payout has been low at 8.73% of profits over last 3 years

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
20.34 27.53 32.52 32.64 22.75 33.09 33.53 34.12 37.15 40.50 42.67 44.20 45.01
15.46 21.49 26.30 26.34 17.78 27.43 27.67 28.26 30.38 33.09 36.51 38.61 38.18
Operating Profit 4.88 6.04 6.22 6.30 4.97 5.66 5.86 5.86 6.77 7.41 6.16 5.59 6.83
OPM % 23.99% 21.94% 19.13% 19.30% 21.85% 17.10% 17.48% 17.17% 18.22% 18.30% 14.44% 12.65% 15.17%
0.54 0.08 0.48 0.83 0.34 0.96 0.52 0.63 0.35 0.38 0.55 0.83 0.54
Interest 0.36 0.04 0.30 0.49 0.56 0.77 0.62 0.68 0.86 0.96 0.91 0.65 1.87
Depreciation 0.41 1.33 1.35 1.57 1.52 1.53 1.62 1.60 1.61 1.68 1.80 1.76 1.77
Profit before tax 4.65 4.75 5.05 5.07 3.23 4.32 4.14 4.21 4.65 5.15 4.00 4.01 3.73
Tax % 10.75% 12.42% 16.44% 25.64% 14.55% 17.13% 13.04% 10.69% 13.12% 14.37% 24.75% 31.17% 16.62%
4.14 4.15 4.22 3.78 2.75 3.59 3.61 3.76 4.05 4.42 3.01 2.77 3.10
EPS in Rs 3.39 3.40 3.45 3.09 2.25 2.94 2.85 2.97 3.20 3.49 2.38 2.19 2.44
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
64 73 78 67 82 112 123 117 110 115 138 172
64 68 73 62 71 95 105 99 90 91 113 146
Operating Profit -0 5 5 6 12 17 17 18 20 24 25 26
OPM % -0% 7% 6% 8% 14% 15% 14% 15% 18% 21% 18% 15%
1 1 1 1 0 2 4 2 1 2 2 2
Interest 4 4 4 4 4 3 1 1 2 2 3 4
Depreciation 2 2 2 2 2 2 2 2 3 6 6 7
Profit before tax -5 0 0 1 6 14 18 17 17 18 17 17
Tax % 1% 44% -267% 32% 19% 27% 31% 26% 25% 18% 13% 21%
-5 0 0 0 5 10 12 12 12 15 15 13
EPS in Rs -5.81 0.10 0.46 0.48 4.91 8.89 10.28 10.04 10.22 12.20 11.86 10.46
Dividend Payout % 0% 0% 0% 0% 0% 12% 10% 5% 10% 8% 8% 10%
Compounded Sales Growth
10 Years: 9%
5 Years: 7%
3 Years: 16%
TTM: 25%
Compounded Profit Growth
10 Years: 65%
5 Years: 2%
3 Years: 2%
TTM: -11%
Stock Price CAGR
10 Years: 42%
5 Years: 2%
3 Years: -9%
1 Year: -45%
Return on Equity
10 Years: 10%
5 Years: 9%
3 Years: 8%
Last Year: 7%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 8 9 10 10 11 12 12 12 12 12 13 13
Reserves 7 7 7 8 15 63 75 110 122 136 181 196
17 15 21 19 18 14 12 11 19 26 26 30
33 33 31 23 30 28 38 43 39 52 57 55
Total Liabilities 65 65 69 60 73 118 137 176 192 226 277 294
23 22 20 19 19 25 24 34 90 92 92 91
CWIP 0 1 0 0 0 0 15 40 0 0 0 0
Investments 0 0 0 0 0 0 0 2 2 2 4 8
42 42 49 41 54 92 97 100 101 131 180 195
Total Assets 65 65 69 60 73 118 137 176 192 226 277 294

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
-2 5 -3 6 4 -5 4 12 13 5 -4 -0
-1 -1 0 -1 -2 -8 -15 -39 -18 -8 -8 -9
2 -4 3 -5 -1 33 -4 21 6 4 28 3
Net Cash Flow -1 1 -0 0 0 20 -14 -6 1 1 17 -6

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 105 102 124 87 114 126 129 137 165 193 159 102
Inventory Days 122 95 95 95 102 77 67 85 28 188 230 237
Days Payable 225 209 187 160 165 118 134 160 161 291 232 152
Cash Conversion Cycle 1 -13 32 22 51 85 62 62 32 91 157 188
Working Capital Days 50 44 80 83 96 135 151 162 166 207 213 178
ROCE % -3% 13% 12% 12% 25% 25% 20% 15% 13% 12% 11% 9%

Shareholding Pattern

Numbers in percentages

Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024
44.83% 43.60% 43.60% 43.60% 43.21% 43.21% 43.21% 43.21% 43.21% 43.21% 43.21% 42.99%
0.35% 0.35% 0.40% 0.35% 1.83% 0.17% 0.19% 0.16% 0.22% 0.22% 0.12% 0.06%
0.00% 0.00% 0.00% 0.00% 0.13% 0.20% 0.20% 0.20% 0.20% 0.67% 0.99% 1.17%
54.82% 56.06% 56.01% 56.06% 54.84% 56.42% 56.40% 56.44% 56.38% 55.90% 55.69% 55.78%
No. of Shareholders 5,5959,1409,3009,1078,3328,2738,2338,2729,41910,25210,63910,652

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls

  • Dec 2021
    Transcript
    Notes
    PPT
  • Nov 2020
    Transcript
    Notes
    PPT
  • Aug 2020
    Transcript
    Notes
    PPT
  • Jun 2020
    Transcript
    Notes
    PPT